Illinois is currently home to 2625 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
NCT05566769
Recruiting
NMOSDCopilot is a digital tool developed for the self-assessment of Neuromyelitis Optica Spectrum Disorder symptoms that impact patients' functioning and quality of life. It has been co-designed with the help of patient advocacy groups, NMOSD patients and medical experts. It includes a smartphone-based application for patients, connected to a web portal developed for healthcare professionals (HCSPs). The patient application is composed of vision, walking, cognition, and dexterity e-active tests... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2024
Locations: NorthShore University HealthSystem, Evanston, Illinois
Conditions: Neuromyelitis Optica
Register for Updates
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636
Recruiting
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies ha... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
10/14/2024
Locations: Northwestern Medicine Fertility and Reproductive Medicine, Chicago, Illinois
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Register for Updates
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
NCT05021835
Recruiting
This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same. Z... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/12/2024
Locations: Northwest Heart Clin. Res., Arlington Heights, Illinois
Conditions: Cardiovascular Risk, Chronic Kidney Disease, Inflammation
Register for Updates
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
NCT06291987
Recruiting
The purpose of this research is to gather information on the safety and effectiveness determining maximum tolerated dose (MTD) of ruxolitinib in combination with ivosidenib in IDH1-mutated advanced-phase Ph-negative MPNs while evaluate the efficacy of ruxolitinib in combination with ivosidenib in IDH1-mutated advanced-phase Ph-negative MPNs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Myeloproliferative Neoplasms
Register for Updates
The HOP-STEP Intervention: Improving Maternal Health in Women With Lupus sIRB
NCT05818254
Recruiting
While the HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) program has been demonstrated to be effective in improving provider confidence, increasing contraception documentation, and facilitating equitable pregnancy planning care in a single sub-specialty clinic here at Duke, the delivery of HOP-STEP may need to be changed to increase its fit with the local context at the University of Chicago Medical Center (UCMC) and subsequent locations. Thus, the investigators... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Systemic Lupus Erythematosus, Contraception
Register for Updates
Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis
NCT05213234
Recruiting
The hypothesis of this study is that appropriate time of day of administration of oral, once daily 5-ASA therapy in alignment with the host circadian rhythms will improve subclinical inflammation and microbial structure/function and increase mucosal 5-ASA levels. All subjects will be randomized to once daily 5-ASA medications at two different times of the day: between 06:00 - 10:00 h or 18:00 - 22:00 h. Three disease assessments will performed at: 1) enrollment just before randomization; 2) mon... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/11/2024
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Ulcerative Colitis
Register for Updates
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195
Recruiting
This is an open-label, multi-center, roll-over study to evaluate the long term safety of ribociclib in combination with other drugs in participants who are participating in a Novartis sponsored global study, that has fulfilled requirements for its primary objective(s), and who in the opinion of the Investigator, would benefit from continued treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: Duly Health and Care, Plainfield, Illinois
Conditions: Metastatic Breast Cancer
Register for Updates
Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years
NCT04821310
Recruiting
The purpose of this study is to explore the outcomes, tolerability and safety of 2 different doses of oral pantoprazole (full healing dose, half healing dose), assigned based upon weight, for the maintenance of healing of erosive esophagitis in pediatric participants aged 1 to 17 years with endoscopically-confirmed, healed erosive esophagitis.
Gender:
ALL
Ages:
Between 1 year and 17 years
Trial Updated:
10/11/2024
Locations: The University of Chicago Medical Center, Chicago, Illinois
Conditions: Esophagitis
Register for Updates
Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy
NCT01429389
Recruiting
The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: Reproductive Genetics Institute, Chicago, Illinois
Conditions: Down Syndrome, Fetal Aneuploidy
Register for Updates
Optimizing Orthodontic Appliances Efficiency With Remote Dental Monitoring and Artificial Intelligence Algorithms
NCT05573308
Recruiting
The decision on aligner changing is based on orthodontists' personal experience and common knowledge that an approximated time span for the aligner have exhausted its biological efficacy. However, a one size fits all approach is not always ideal, as an average determined time is not taken into account of a patient's individual biological response. The aligners could be progressed earlier than the determined time, or they may stay inactive for a while, waiting for the in-office visit. Dental Moni... Read More
Gender:
ALL
Ages:
Between 12 years and 70 years
Trial Updated:
10/10/2024
Locations: Orthodontic Specialists of Lake County (Antioch), Antioch, Illinois
Conditions: Malocclusion, Misaligned Teeth
Register for Updates
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
NCT03942653
Recruiting
A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2024
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois
Conditions: Salivary Gland Carcinoma
Register for Updates
Ribociclib and Bicalutamide in AR+ TNBC
NCT03090165
Recruiting
This is an open label, multi-institutional, single arm phase II trial of ribociclib in combination with bicalutamide in advanced AR+ triple-negative breast cancer. No randomization or blinding is involved.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2024
Locations: University of Illinois Cancer Center, Chicago, Illinois
Conditions: Triple Negative Breast Cancer
Register for Updates